Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reneo Pharmaceuticals Inc (NQ: RPHM )

1.760 +0.030 (+1.73%)
Streaming Delayed Price Updated: 1:51 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Topline data results from the pivotal STRIDE study are expected in December 2023 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Topline data results from the STRIDE study are expected in December 2023 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Announces Pricing of Public Offering of Common Stock
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
Topline data from the STRIDE study expected in the fourth quarter of 2023 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.